Shaw AT, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. J Clin Oncol 35, 2017 (suppl; abstr LBA9008).
Overleving Europese adolescenten en jongvolwassenen met kanker is verbeterd
apr 2024 | Leukemie, Neuro-oncologie